| |
Simplify the complexity of global commercialization with the World Orphan Drug Alliance (WODA), an alliance of like-minded full-service commercial distributors for rare and specialty portfolios. Discover WODA's unique global approach with local focus.
|
|
| By Eric Sagonowsky Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer. |
|
|
|
By Annalee Armstrong Exscientia is initiating “efficiency measures” to save cash, which will include a workforce reduction of around a quarter of staff while preserving the AI drug hunter’s existing pipeline. |
By Nick Paul Taylor Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications. |
By Angus Liu China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer. |
|
Fina Biosolutions has a clear mission: Make conjugate vaccines more affordable. FinaBio is unique in that it is a privately held, self-funded biotechnology company. The company needed to implement key strategies and solutions for cGMP manufacturing of EcoCRM®, FinaBio’s CRM197. Dowload to learn more.
|
|
By Conor Hale According to a report from the San Diego Union-Tribune, the company will shutter operations at the end of this week, while laying off its remaining staff and leadership. |
By Kevin Dunleavy Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer immunotherapy as a “watershed moment,” the FDA has signed off on Imdelltra (tarlatamab) to treat patients with extensive-stage small-cell lung cancer (ES-SCLC). |
By James Waldron Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the process. |
By Helen Floersh Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time. |
By Nick Paul Taylor A survey has shown the demographics most likely to be distrustful of the FDA. The results suggest the agency needs to win the trust of conservative women in rural communities who are in poor health or dissatisfied with their healthcare. |
By Zoey Becker Pfizer downsized much of its operations at the site, where it first discovered Viagra, last year. Now, Asymchem has inked a lease to take over the facility. Asymchem will begin operations there this summer and employ some former Pfizer staffers. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| eBookThis eBook offers insights for business leaders looking to do more with reduced budgets by using the power of SmartIQ’s true forms automation to eliminate the need to print, sign, and scan/mail physical documents, increase operational efficiency, and reduce disparate systems. Sponsored by: SmartComms LLC |
| ResearchDownload this research report to discover how a new predictive model built on consumer attitudinal data can generate improved results for health marketers. Sponsored by: Quad Media |
| Whitepaper Virtual care programs represent a compelling opportunity for decision makers in life sciences companies to drive growth, innovation, and value creation. Download now to learn more. Sponsored by: Wheel |
| WhitepaperHow one top pharma increased literature reviews efficiency by 3x powered by AI -- download today Sponsored by: IQVIA |
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperSmall molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
